📋 Tender Overview
The Integrate Study : An Adaptive Platform Trial For The Development Of A New Intervention To Combat Lassa Fever In Africa
Improving Lassa Fever Control In Nigerialassa Fever (Lf) Is A Severe Illness With A High Mortality Rate Among Hospitalised Patients In West Africa. Currently, There Is No Secure And Efficient Treatment For Lf, With The Exception Of Ribavirin, Which Some Experts Question. The Implementation Of An Effective Treatment Would Reduce Mortality Rates And Alleviate Socioeconomic Implications. Nigeria Bears The Highest Burden Of Lf, Accounting For 80 % Of Global Cases. The Eu-Funded Integrate Project Seeks To Establish A Clinical Trial Platform To Evaluate Both Repurposed And New Drugs In Nigeria And Other Affected Countries. By Facilitating Technology Transfer And Training, Both Between North And South And Among Different Countries In The South, The Project Aims To Enhance The Capacity Of Sites, Laboratories And Medical Care Facilities.
Funded Under
Health
Total Cost
€ 8 800 000,00
Eu Contribution
€ 8 000 000,00
Coordinated By
Universite De Bordeaux
France
